Abstract
Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.
| Original language | English |
|---|---|
| Pages (from-to) | 196-200 |
| Number of pages | 5 |
| Journal | Journal of Surgical Oncology |
| Volume | 66 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 1997 Nov |
| Externally published | Yes |
Fingerprint
Keywords
- Carcinomatous pleuritis
- Cisplatin
- Intracavitary chemotherapy
- Malignant effusion
- Non-small cell lung cancer
ASJC Scopus subject areas
- Surgery
- Oncology
Cite this
Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis. / Ichinose, Yukito; Yano, Tokujiro; Asoh, Hiroshi; Yokoyama, Hideki; Fukuyama, Yasuro; Miyagi, Jun; Kuninaka, Shinji; Terazaki, Yasuhiro.
In: Journal of Surgical Oncology, Vol. 66, No. 3, 11.1997, p. 196-200.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis
AU - Ichinose, Yukito
AU - Yano, Tokujiro
AU - Asoh, Hiroshi
AU - Yokoyama, Hideki
AU - Fukuyama, Yasuro
AU - Miyagi, Jun
AU - Kuninaka, Shinji
AU - Terazaki, Yasuhiro
PY - 1997/11
Y1 - 1997/11
N2 - Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.
AB - Background and Objectives: We recently developed a new intraoperatire intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy in non-small cell lung cancer patients. In the present study, the efficacy and adverse events of this treatment as well as the pharmacokinetics of cisplatin in the blood after the treatment were evaluated. Patients and Methods: Twenty-one patients received the treatment for 15 minutes after completing the intrathoracic surgical procedures. The total and free platinum levels in the blood of five patients were then measured. As a control, 29 patients without such treatment were reviewed retrospectively. Results: The survival rates in the treatment and non- treatment groups were similar. The pleural disease free survival of the treated patients was, however, significantly higher than that of the non- treated patients. Such pleural disease as effusion and the growth of the pleural disseminated tumors only appeared in three of the 21 (14%) treated patients while 26 of 29 (90%) non-treated patients had clinically detected pleural disease. The blood platinum levels after the treatment were extremely low and such low levels probably induced no systemic adverse events after the treatment. The only adverse event of this treatment was an increase in the postoperative drainage volume. Conclusions: These observations seem to suggest that intraoperative intrapleural hypotonic cisplatin treatment for carcinomatous pleuritis found at thoracotomy can, at least, delay the appearance of the pleural disease without any adverse events.
KW - Carcinomatous pleuritis
KW - Cisplatin
KW - Intracavitary chemotherapy
KW - Malignant effusion
KW - Non-small cell lung cancer
UR - http://www.scopus.com/inward/record.url?scp=0030712421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030712421&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7
DO - 10.1002/(SICI)1096-9098(199711)66:3<196::AID-JSO8>3.0.CO;2-7
M3 - Article
VL - 66
SP - 196
EP - 200
JO - Journal of Surgical Oncology
JF - Journal of Surgical Oncology
SN - 0022-4790
IS - 3
ER -